Rabbit Polyclonal MYOD1 antibody. Suitable for WB, sELISA and reacts with Mouse, Human samples. Cited in 35 publications.
View Alternative Names
BHLHC1, MYF3, MYOD, MYOD1, Myoblast determination protein 1, Class C basic helix-loop-helix protein 1, Myogenic factor 3, bHLHc1, Myf-3
- WB
Ap
Western blot - Anti-MyoD1 antibody (AB64159)
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab64159 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution ab133406.
ab64159 detects a band at 45 kDa, while this differs to its predicted molecular weight of 34kDa, the banding pattern observed is consistent with what has been described in the literature PMID : 19352326.
All lanes:
Western blot - Anti-MyoD1 antibody (ab64159) at 1 µg/mL
Lane 1:
Skeletal Muscle (Mouse) Tissue Lysate at 20 µg
Lane 2:
Rh30 Whole Cell Lysate at 5 µg
Secondary
All lanes:
Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/50000 dilution
Predicted band size: 34 kDa
Observed band size: 45 kDa,47 kDa
true
Exposure time: 1min
- sELISA
Unknown
Sandwich ELISA - Anti-MyoD1 antibody (AB64159)
Standard Curve for Myo-D; dilution range 1 pg/ml to 1 ug/ml using Capture Antibody Mouse monoclonal [5.2F] to MyoD1 (ab16148) at 5ug/ml and Detector Antibody Rabbit polyclonal to MyoD1 (ab64159) at 0.1ug/ml.
- WB
CiteAb
Western blot - Anti-MyoD1 antibody (AB64159)
Western Blotting using Anti-MyoD1 antibody, ab64159. Publication image from Zhang, H. et al., 2020, Cell Res, 32839552. Legend direct from paper.
Necroptosis-deficient mice exhibit muscle regeneration defects.a Representative of H&E staining of TA muscle cross-sections from both uninjured (Day 0) and injured (7 and 15 days after CTX injection) WT and Mlkl−/− mice. Scale bars, 50 µm. b Quantification of myofiber sizes from cross-sectional areas (CSAs) of injured mice (7 days after CTX injection) and myofibers with multiple central nuclei out of total cells with central nuclei (in vivo fusion index) 15 days post CTX injection. 3 different views were counted for each mouse. The data are expressed as the means ± SD. n = 6 each for WT and Mlkl−/− mice. c Immunofluorescence staining of MYH3 (green) and Laminin (red) in TA muscle cross sections from both uninjured (Day 0) and injured (4 days after CTX injection) mice. Nuclei were identified by staining with DAPI. Scale bars, 25 µm. d Quantification of the MYH3+ myofiber sizes from CSAs of injured mice (4 days after CTX injection, as representatively shown in c). The sizes of 200 adjacent MYH3+ myofibers were measured for each mouse. Each dot represents an individual myofiber. The data are expressed as the means ± SD. n = 6 each for WT and Mlkl−/− mice. e Immunoblotting analysis of MyoD, MyoG, and MYH3 expression in uninjured (Day 0) or injured (4 days after CTX injection) TA muscles using antibodies as indicated. Whole TA muscle lysates were exacted, as described in Materials and Methods, from 3 mice and pooled together for each condition. HSP70 serves as the loading control. The asterisk (*) denotes the non-specific band. Experiments were repeated independently for three times. f Quantification of the MuSCs in injured TA muscles (3 days after CTX injection) by FACS analysis. MuSCs were isolated as described in Materials and Methods. The histogram represents the percentage of MuSCs (PI−CD11b−CD31−CD45−Sca1−Vcam+ population) out of the total digested mono-nucleus cells. Each dot represents an individual mouse. The data are expressed as the means ± SD. n = 6 each for WT and Mlkl−/− mice. g Immunofluorescence staining of Ki67 (green) and Pax7 (red) in freshly isolated MuSCs (3 days after CTX injection). MuSCs were isolated by FACS and fixed on PDL/Collagen-I pre-coated coverslip, as described in Materials and Methods, followed by immunofluorescence staining using the antibodies as indicated. Nuclei were identified by staining with DAPI. Scale bars, 5 µm. h Quantification of the Ki67+/Pax7+ cells as shown in g. MuSCs isolated from 3 mice were pooled together for immunofluorescence staining in each group. The histogram represents the percentage of Ki67+/Pax7+ cells out of 200 Pax7+cells per genotype. The data are expressed as the means ± SD of 6 images. i qRT-PCR analysis of Ccnd1 mRNA level in MuSCs isolated from injured mice (3 days after CTX injection). The mRNA level of Gapdh was used as the internal control. MuSCs isolated from 3 mice were pooled together for qRT-PCR analysis. The data are expressed as the means ± SD of 3 technical repeats. P values for b, d, and f were determined by unpaired two-tailed t-test; P values for h and i were determined by unpaired two-tailed t-test with Welch’s correction. **P < 0.01; ***P < 0.005. CTX, cardiotoxin; TA, tibialis anterior.
false
Reactivity data
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
MyoD1 plays an important role in muscle differentiation by activating muscle-specific genes. It belongs to the myogenic regulatory factor family and often operates within a protein complex alongside Myf5 and myogenin aiding in the conversion of mesodermal stem cells into muscle cells. These partnerships enhance its ability to initiate the muscle-specific gene expression that drives myogenesis. MyoD1 acts like a molecular switch shifting cells into the pathway leading to muscle formation.
Pathways
MyoD1 is an integral component of myogenesis and muscle regeneration pathways. MyoD1 interacts with key pathway components such as Myf5 and MRF4 which reinforce MyoD1 activity in muscle tissue lineage determination and cell cycle arrest during differentiation. The activity of MyoD1 in these pathways highlights its role in skeletal muscle growth. MyoD1 also demonstrates functional redundancy with Myogenin as both share overlapping roles in these critical pathways.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (35)
Recent publications for all applications. Explore the full list and refine your search
eLife 13: PubMed40960171
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of cachexia, sarcopenia and muscle 16:e13708 PubMed39887939
2025
Applications
Unspecified application
Species
Unspecified reactive species
Arteriosclerosis, thrombosis, and vascular biology 43:2023-2029 PubMed37675635
2023
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of physiology 601:961-978 PubMed36715084
2023
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of biological chemistry 299:102978 PubMed36739949
2023
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 13:6907 PubMed36376321
2022
Applications
Unspecified application
Species
Unspecified reactive species
Biomolecules 12: PubMed36139126
2022
Applications
Unspecified application
Species
Unspecified reactive species
Neurourology and urodynamics 41:1539-1552 PubMed35842827
2022
Applications
Unspecified application
Species
Unspecified reactive species
Biochemical and biophysical research communications 609:163-168 PubMed35436627
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cells 11: PubMed35406727
2022
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com